Randomized phase II study of maintenance pemetrexed, bevacizumab, and pemetrexed+bevacizumab after induction chemotherapy with carboplatin+pemetrexed in advanced nonsquamous NSCLC.

Randomized phase II study of maintenance pemetrexed, bevacizumab, and pemetrexed+bevacizumab after induction chemotherapy with carboplatin+pemetrexed in advanced nonsquamous NSCLC. - Randomized phase II study of maintenance PEM, BEV, and PEM+BEV

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006620

Enrollment

Registered

2012-01-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonsquamous NSCLC

Interventions

pemetrexed bevacizumab pemetrexed+bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Induction chemotherapy 1.nonsquamous NSCLC 2.stage IIIB or IV 3.Age <75 4.ECOG PS 0-1 5.normal organ function 6.Written informed consent Maintenance chemotherapy 1.non-PD after 4 cycles of induction chemotherapy 2.ECOG PS 0-1 3.normal organ function

Exclusion criteria

Exclusion criteria: Induction chemotherapy 1.severe comorbit disease 2.history of hemoptysis, coagulation disorder and thrombosis 3.tumor cavitation 4.invasion to the major vessel 5.myocardial infarction or brain infarction within 6 months 6.pregnant or lactating woman 7.brain metastasis with high risk of bleeding 8.interstitial pneumonia 9.effusion needed drainage 10.surgery within 4 weeks 11.radiation within 4 weeks 12.drainage within 1 week 13.double cancer Maintenance chemotherapy 1)PD after induction chemotherapy 2)hemoptysis 3)bleeding tendency or thrombosis 4)ECOG PS 2-4

Design outcomes

Primary

Measure	Time frame
1-year progression-free survival rate from randomization.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026